Achieve Life Sciences, Inc.

Achieve Life Sciences, Inc. is a late-stage pharmaceutical company focused on developing and commercializing cytisinicline for nicotine independence. Cytisinicline is a naturally occurring alkaloid that interacts with nicotine receptors in the brain, reducing the severity of nicotine withdrawal symptoms. The company operates in Canada, the United States, and the United Kingdom. Achieve Life Sciences aims to provide a treatment option for individuals seeking to quit smoking or using other nicotine products.

Achieve Life Sciences, Inc. is listed on the Nasdaq Capital Market (NasdaqCM) under the ticker symbol ACHV. The company's stock is traded in United States Dollars (USD). As a US-based company listed on a US exchange, its financial reporting and stock price are denominated in USD, making it accessible to investors trading in US markets.

Achieve Life Sciences operates in the Healthcare sector, specifically within the Biotechnology industry. As a biotechnology company, it focuses on research, development, and commercialization of pharmaceutical products. In particular, Achieve Life Sciences is a late-stage pharmaceutical company dedicated to developing cytisinicline for nicotine independence, which falls under the broader biotechnology and pharmaceutical categories.

Achieve Life Sciences, Inc. is headquartered in Bothell, Washington, United States. The company serves markets in Canada, the United States, and the United Kingdom. Its primary focus is on developing and commercializing cytisinicline for nicotine independence in these regions. The company has license and supply agreements with Sopharma AD and the University of Bristol to support its operations and product development.

Achieve Life Sciences is a late-stage pharmaceutical company that generates revenue through the development and commercialization of cytisinicline for nicotine independence. The company has entered into license and supply agreements with Sopharma AD and the University of Bristol to secure the supply and intellectual property rights for cytisinicline. As a development-stage company, it likely does not yet have significant product sales revenue but may generate revenue through licensing fees, milestone payments, or partnerships. Its business model focuses on bringing cytisinicline to market as a treatment for nicotine addiction.